Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 26.65% is 44% above its 4-year average of 18.56%, near the high end of its 4-year range (-75.62%–35.57%).
19.54% above its 12-month average of 22.29%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 35.57%.
NET PROFIT MARGIN
26.65%
NET PROFIT MARGIN AVG TTM
22.29%
NET PROFIT MARGIN AVG 3Y
18.57%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+19.54%
CURRENT VS 3Y AVG
+43.55%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 644 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Indivior Pharmaceuticals Inc
Market Cap
$4.41B
Net Profit Margin
26.65%
TTM Avg
22.29%
3Y Avg
18.57%
5Y Avg
N/A
Market Cap
$4.45B
Net Profit Margin
-20.73%
TTM Avg
-55.30%
3Y Avg
-87.73%
5Y Avg
-105.64%
Market Cap
$4.38B
Net Profit Margin
-55.82%
TTM Avg
-71.50%
3Y Avg
-84.24%
5Y Avg
-84.24%
Market Cap
$4.35B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.62B
Net Profit Margin
8.43%
TTM Avg
-12.40%
3Y Avg
-46.69%
5Y Avg
-46.69%
Market Cap
$4.64B
Net Profit Margin
3.68%
TTM Avg
3.96%
3Y Avg
4.48%
5Y Avg
3.62%
Market Cap
$4.65B
Net Profit Margin
3.19%
TTM Avg
-1.95%
3Y Avg
-11.66%
5Y Avg
-17.12%
Market Cap
$4.68B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.13B
Net Profit Margin
12.82%
TTM Avg
-6.21%
3Y Avg
-4.84%
5Y Avg
-11.63%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indivior Pharmaceuticals Inc (INDV) | $4.41B | 26.65% | 22.29% | 18.57% | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.45B | -20.73% | -55.30% | -87.73% | -105.64% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.38B | -55.82% | -71.50% | -84.24% | -84.24% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.35B | 0.00% | 0.00% | 0.00% | 0.00% |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 8.43% | -12.40% | -46.69% | -46.69% |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 3.68% | 3.96% | 4.48% | 3.62% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.65B | 3.19% | -1.95% | -11.66% | -17.12% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.68B | 0.00% | 0.00% | 0.00% | 0.00% |
| LivaNova PLC (LIVN)vs › | $4.13B | 12.82% | -6.21% | -4.84% | -11.63% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.08B | -248.83% | -379.86% | -278.01% | -170.03% |
Operating Margin
21.4%
Net Profit Margin
26.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 35.57% |
| 2026-03-31 | 28.08% |
| 2025-12-31 | 28.49% |
| 2025-09-30 | 13.38% |
| 2025-06-30 | 5.96% |
| 2025-03-31 | 17.67% |
| 2024-12-31 | 19.73% |
| 2024-09-30 | 1.30% |
| 2024-06-30 | -32.44% |
| 2024-03-31 | 21.48% |
| 2023-12-31 | 18.43% |
| 2023-09-30 | -49.82% |
| 2023-06-30 | 14.13% |
| 2023-03-31 | 17.39% |
| 2022-12-31 | -75.62% |
| 2022-09-30 | 17.67% |
| 2022-06-30 | 21.72% |
| 2022-03-31 | 19.81% |
| 2021-12-31 | 16.14% |
